You are here

Development of a 3D mammotomograph with novel techniques to overcome limitations

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44CA125924-02
Agency Tracking Number: CA125924
Amount: $773,269.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Solicitation Year: 2009
Award Year: 2009
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
DUNS: 622988793
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (919) 225-3965
Business Contact
Phone: (919) 225-3965
Research Institution
DESCRIPTION (provided by applicant): This proposal combines the expertise of world renowned medical center collaborators with the experience obtained from our SBIR Phase I project to provide a 3rd generation 3D breast CT scanner suitable for a planned patient trial. X-ray mammography (XRM) has recognized limits including relatively high false negative rates. Other disadvantages include uncomfortable breast compression (possibly reducing participation rates), relatively high dose to the breast, and low positive predictive value, especially for radiographically dense breasts, and 2D images having severely overlapped tissues. The emergence of compact, high-quality digital X-ray imaging detectors, together with nearly exponential growth in computing power and corresponding price reductions, allows for the natural evolution of fully-3D dedicated breast imaging. The contemporary breast imaging approach using tomosynthesis yields morphological, pseudo-3D images (asymmetric volume image resolution with highly aliased and blurred artifacts) and with otherwise no quantifiable metrics due to the highly insufficiently sampled breast volume. The fully-3D dedicated breast Computed mammoTomography (CmT) solution we are developing has the potential for improved detection of breast lesions through the removal of contrast-reducing overlying tissue with images having lt500 micron isotropic resolution, as well as the added benefits of uncompressed breast imaging for greater patient comfort, and breast dose equal to or less than that of current dual view screening mammography. Since it is well known that breast compression affects flow of contrast agents, immobilized but uncompressed breast CmT imaging proposed here also allows for contrast enhanced and other kinetic based studies. Ultimately, we expect this technology to result in improved positive predictive value with earlier cancer detection and reduced morbidity and mortality. In NCI-funded work, all Aims have been accomplished in the Phase I SBIR, and we have confirmed that the next generation scanner will be able to fully image the breast and chest wall of a prone patient with uncompressed breasts without unnecessary and uncomfortable contortions of the patient. Our findings have indicated that a unique combination of complex motion capabilities together with modified system and bed components are required to meet this end. As far as we know, this will represent the first dedicated breast CT system with these capabilities and solves one of the major issues remaining for this technology to be commercially successful, namely the ability to image the full breast and chest wall, in a short period of time, without moving the patient during the scan, and maximizing patient comfort. Therefore, the main goals of this Phase II proposal will be to fabricate a clinic-ready scanner containing all modifications indicated in the Phase I and to perform clinical evaluations of this scanner with a small cohort of patients. These goals will be approached through the following Phase II Specific Aims over a two-year period: Specific Aim 1 is to fabricate a clinic-ready scanner using the results of the Phase I SBIR. Tasks will include: (1) implementation of new larger Varian 4030E detector and end-on Comet X-ray tube; (2) implementation of redesigned patient bed specifically adapted to the new system; and (3) implementation and automation of unique orbits and vertical motion capability of system determined in Phase I to maximize the breast volume scanned. Specific Aim 2 is to upgrade front-end and back-end software systems, including (1) implementation of improved synchronization and software robustness to FDA standards; (2) implementation of improved reconstruction algorithm for faster and more practical reconstructions; (3) implementation of front-end GUI for use by trained technician; (4) automation of back-end process for reconstructions and data presentation; and (5) inclusion of literature based scatter correction. Specific Aim 3 is to perform a limited patient trial with a cohort of 25 locally advanced breast cancer patients for three purposes: (1) evaluation of a developed simple mechanism for uncompressed breast immobilization and biopsy capability; (2) evaluation of modified system on women of varying breast and body sizes to confirm system flexibility and ability to image to chest wall; (3) comparison study of CmT versus digital x-ray mammography where patients will undergo both scans. Criteria for success for each Aim are defined in the more detailed Specific Aims section of the proposal. Therefore, the primary goal of this proposal is to produce a clinic-ready and saleable next generation system suitable for placement in practicing clinics to be used for collection of clinical trial results suitable for FDA submission and subsequent sale of systems for commercial use. These systems will be, to our knowledge, the only dedicated breast CT systems with the complex motion capabilities necessary for comfortable and complete breast, and also capable of chest wall imaging. Overall success of this project will be indicated by a complete system useable by trained technicians in a clinical setting and the indication from initial patient trials that the system measures up to the anticipated advantages that have been indicated by our previous results. Phase III is anticipated to involve production of several commercially viable products for placement in several clinics for larger patient trials. The sampling techniques developed here could also be packaged as products in their own right. PUBLIC HEALTH RELEVANCE: This R44 proposal seeks Phase II funding to produce a clinic-ready, commercially viable, next generation dedicated 3D breast CT device and conduct initial patient trials to evaluate the ability of the system to image breast cancers as compared with conventional digital mammography. In the USA, breast cancer in women is one of the leading causes of malignancy and the second leading cause of death due to cancer (after lung cancer). The earlier a lesion is detected, the better the chances for survival. Our primary hypothesis has been that a dedicated device for 3-dimensional, uncompressed, whole breast imaging will significantly improve cancer detection, thereby reducing morbidity and mortality. Preliminary results have indicated a significant potential advantage and therefore indicate that 3D breast CT should play a prominent role as an important tool in a clinical setting for mammographers. This project serves to provide a clinic-ready scanner able to comfortably image the entire breast without breast compression along with the chest wall of a prone patient, overcoming a major challenge for dedicated breast imaging, and to provide initial patient results confirming patient benefits and therefore commercial potential. Subsequent Phase III activities will involve production of several systems for placement in multiple clinics and conduction of further clinical trials for FDA approval. Academic research markets will also be approached for sale of additional units.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government